Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate

被引:53
作者
Streisand, JB [1 ]
Busch, MA [1 ]
Egan, TD [1 ]
Smith, BG [1 ]
Gay, M [1 ]
Pace, NL [1 ]
机构
[1] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84132 USA
关键词
cancer pain management; transmucosal drug delivery;
D O I
10.1097/00000542-199802000-00006
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Background: The pharmacokinetics of a single dose (15 mu g/kg) of oral transmucosal fentanyl citrate (OTFC) have been characterized. A range of doses may eventually be used in clinical practice. The goal of this study was to determine if the pharmacokinetics of OTFC are dose proportional for doses ranging from 200 to 1,600 mu g. Methods: Twelve healthy male volunteers mere studied on four different occasions, receiving 200, 400, 800, and 1,600 mu g OTFC in a double-blind, randomized protocol Venous blood samples were collected at selected times during and after dosing for a 24-h period and assayed for fentanyl using a radioimmunoassay. Maximum concentration, time to maximum concentration, area under the curve, and elimination half-life mere determined for each dose administered. In addition, respiratory rate, need for verbal prompting to breathe, and supplemental oxygen requirements were noted. Results: Mean fentanyl concentration time curves were similarly shaped with increasing doses. Both peak concentrations and area under the curve increased linearly with an increase in dose, whereas time to reach peak serum concentrations did not vary significantly between doses. Except for the 200-mu g dose, the apparent elimination half-life remained relatively constant (358-386 min). The incidence of low respiratory rate, supplemental oxygen requirement, and number of breathing prompts significantly increased with increasing doses. Conclusions: Oral transmucosal fentanyl citrate exhibits dose-proportional pharmacokinetics over the dose range of 200-1,600 mu g.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 7 条
[1]
BIBALDI M, 1982, ABSORPTION KINETICS, P145
[2]
ORAL TRANSMUCOSAL FENTANYL CITRATE PREMEDICATION IN PATIENTS UNDERGOING OUTPATIENT DERMATOLOGICAL PROCEDURES [J].
GERWELS, JW ;
BEZZANT, JL ;
LEMAIRE, J ;
PAULEY, LF ;
STREISAND, JB .
JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1994, 20 (12) :823-826
[3]
HOLLANDER M, 1973, NONPARAMETRIC STAT, P147
[4]
MATHER LE, 1994, ANAESTHETIC PHARM RE, V2, P260
[5]
INTRAVENOUS FENTANYL KINETICS [J].
MCCLAIN, DA ;
HUG, CC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (01) :106-114
[6]
ABSORPTION AND BIOAVAILABILITY OF ORAL TRANSMUCOSAL FENTANYL CITRATE [J].
STREISAND, JB ;
VARVEL, JR ;
STANSKI, DR ;
LEMAIRE, L ;
ASHBURN, MA ;
HAGUE, BI ;
TARVER, SD ;
STANLEY, TH .
ANESTHESIOLOGY, 1991, 75 (02) :223-229
[7]
Oral transmucosal etomidate in volunteers [J].
Streisand, JB ;
Jaarsma, RL ;
Gay, MA ;
Badger, MJ ;
Maland, L ;
Nordbrock, E ;
Stanley, TH .
ANESTHESIOLOGY, 1998, 88 (01) :89-95